Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3
For advanced gastric cancer, surgical resection is the only curable therapeutic strategy. According to minimally invasive approach is adopted in various field of oncologic surgery, laparoscopic gastrectomy with lymph node dissection is becoming a standard not only for early gastric cancer but also for advanced gastric
| Condition(s) | Gastric Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | For advanced gastric cancer, surgical resection is the only curable therapeutic strategy. According to minimally invasive approach is adopted in various field of oncologic surgery, laparoscopic gastrectomy with lymph node dissection is becoming a standard not only for early gastric cancer but also for advanced gastric cancer. The greater omentum is an organ is known to play a role in removing bacteria in the abdominal cavity as a primary defense. Complete resection of the greater omentum has been considered essential to ensure the elimination of micrometastasis during surgery for advanced gastric cancer. However, the oncological effect of total omentectomy is still lack of evidence. Especially in minimal invasive gastrectomy, total omentectomy procedure is known to increases the operating |
| Who can participate | Inclusion Criteria: * Histologically proven adenocarcinoma of the stomach * Age between 20 to 85 years old * ECOG PS 0-1, ASA class I-III * Endoscopically Borrmann type I, II, III * Clinical T3 and T4a tumors with or without regional lymph node metastases (cT3N0M0\~T4aN3M0) * Capable of minimal invasive radical subtotal gastrectomy with R0 resection in preoperative examinations * Patients who signed an written consent form approved by the Institutional Review Board(IRB) after receiving sufficient explanations of the contents of the clinical trial * Domestic patients who are able to follow up for 3 years after surgery Exclusion Criteria: * Confirmed distant metastasis in preoperative examinations * Confirmed metastasis in abdominal cavity or distant organs during surgery * Confirmed no infi |
| Ages | 20 Years to 85 Years |
| Sex | All |
| Lead sponsor | Gangnam Severance Hospital |
| Locations | Seoul, South Korea |
| Start date | 2024-06-26 |
| NCT ID | NCT06608381 |
| Official listing | https://clinicaltrials.gov/study/NCT06608381 |